Maintenance Regorafenib Significantly Delays Disease Progression After First-Line Treatment in Patients with Advanced Non-Adipocytic Soft Tissue Sarcomas By Ogkologos - April 28, 2025 852 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the EREMISS study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Mom Finding Out Baby’s Gender Uncovers Rare Condition When Doctors See... November 7, 2019 Superior Prognostic Accuracy of Integrated 15-GEP/PRAME Classifier Over 15-GEP Alone in... August 22, 2024 Mesothelioma Awareness Day: Spotlight on the PrE0506/DREAM3R Clinical Trial September 23, 2021 Plant-Based Diets and a New Treatment Combination for Prostate Cancer: Research... February 16, 2023 Load more HOT NEWS Stealing Strategies from Cancerous T Cells May Boost Immunotherapy Using Technology to Find Cancers Early and Exercise Improves Sexual Health... Study Explores Jaw Problem Linked to Zoledronic Acid, Finds Risk Factors Latest episode of our podcast for cancer researchers
